Drs. Sighild Lemarchant and Mélissa Sourioux, Axoltis Pharma – Preclinical R&D department, will participate to AD/PD™2022, which will take place online and onsite March 15-20, 2022. Our exciting results about the mechanism of action and the targets engaged by our product NX210c, ensuring synaptic transmission and BBB integrity reinforcement, will be presented. This confirms that our multi-properties product, which is now at clinical stage of development, has a large broad of applications in neurological pathologies.